title: Management of non-alcoholic fatty liver disease in 2015.
abstract: There is no single pharmacologic therapy that has been approved to treat nonalcoholic fatty liver disease in the general population. The backbone of therapy currently includes intensive lifestyle modification with established targets for diet and weight loss. The use of unsweetened, unfiltered coffee along with limiting high fructose corn syrup have emerged as beneficial dietary recommendations. The use of empiric oral hypoglycemic agents and vitamin E, however, has not been widely accepted. Developing bariatric surgical techniques are promising, but additional studies with long-term follow up are needed before it can be widely recommended. Finally, liver transplantation is an increasingly frequent consideration once complications of end-stage disease have developed. The future treatment of those with nonalcoholic fatty liver disease will likely involve a personalized approach. The importance of the gut microbiome in mediating hepatocyte inflammation and intestinal permeability is emerging and may offer avenues for novel treatment. The study of anti-fibrotic agents such as pentoxifylline and FXR agonists hold promise and new pathways, such as hepatocyte cannabinoid receptor antagonists are being studied. With the incidence of obesity and the metabolic syndrome increasing throughout the developed world, the future will continue to focus on finding novel agents and new applications of existing therapies to help prevent and to mediate the progression of nonalcoholic fatty liver disease.
authors.affiliation: Neel Malhotra, Melanie D Beaton, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 3A5, Canada.
authors.forename: Neel
authors.initials: N
authors.lastname: Malhotra
authors.affiliation: Neel Malhotra, Melanie D Beaton, Department of Medicine, Division of Gastroenterology, Western University, London, ON N6A 3A5, Canada.
authors.forename: Melanie D
authors.initials: MD
authors.lastname: Beaton
keywords: Liver fibrosis; Lobular inflammation; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis